Thursday, 20 Feb 2020

You are here

Biologic Therapy Improves Psoriasis and Reduces CV Inflammation

Psoriasis confers a significant risk of comorbidity, but is psoriasis associated with increased coronary inflammation and is this risk attenuated by biologic therapy? 

JAMA Cardiology has published a cohort study of 134 consecutive patients with moderate to severe psoriasis, showing that biologic therapy was associated with a significant decrease in coronary inflammation as assessed by perivascular fat attenuation index, a marker of coronary inflammation associated with cardiovascular outcomes. Patients not receiving biologic therapy had no change in perivascular fat attenuation index at 1 year.

Researchers assessed coronary inflammation using the perivascular fat attenuation index (FAI), an assessment of coronary inflammation coronary computed tomography angiography (CCTA).

Most of the 134 psoriasis patients (mean 51.1 years; 62.5% male) had low cardiovascular (CV) risk with 10-year Framingham Risk Score of 3% (1%-7%) and moderate to severe skin disease.

Biologic agents were used in 82/134 patients and not used in the remaining 52.  Biologic therapies included TNF inhibitors, anti-IL-12/23, or anti–IL-17 agents.

Focal coronary atherosclerotic plaque was seen in 46 patients at baseline.

Biologic therapy was associated with a significant decrease in FAI at 1 year (baseline FAI −71.22 HU vs −76.09 HU at 1 year; P < .001) concurrent with skin disease improvement (median baseline PASI = 7.7 vs  PASI = 3.2 at 1 year; P < .001).

For those not on biologics, there was no change in FAI (baseline FAI, −71.98 vs −72.66 at 1 year; P = .39).

FAI changes were consistent among patients receiving different biologic agents (TNFi, IL-12/23 or IL-17 inhibitors). 

Control of moderate to severe psoriasis with biologic agents was associated with reduced coronary inflammation assessed by perivascular FAI. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Bimekizumab Effective in Active Psoriatic Arthritis

Interleukin 17 IIL-17) is important in the pathogenesis of psoriatic disease, with most current approaches targeting IL-17A. Now there is a noveal approach showing that dual neutralisation of IL-17A and IL-17F in psoriatic arthritis arthritis patients results in clinically significant improvement.

Upadacitinib Effective in Phase 3 Psoriatic Arthritis Study

Abbvie has announced top line results of their SELECT-PSA trial of upadacitinib (UPA), wherein both the 15 and 30 mg doses met the primary endpoint of ACR20 response at week 12 and demonstrated radiographic inhibition at week 24.

Which Biologics are Best in Psoriasis

A metanalysis of phase II, III and IV trials in moderate to severe plaque psoriasis suggests comparative efficacy biologic treatments, but that that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were shown to have the past skin (PASI) response rates.

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.

Best of 2019 - SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.